User:Mr. Ibrahem/Acalabrutinib

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). For CLL it may be used initially or in those who have failed other treatment. It is taken by mouth.

Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. Other side effects may include infection, bleeding, further cancer, and atrial fibrillation. Use in pregnancy may harm the baby. It is a Bruton's tyrosine kinase inhibitor, which slows the build-up of cancerous B cells.

Acalabrutinib was approved for medical use in the United States in 2017 and Europe in 2020. In the United Kingdom a month of medication costs the NHS about £5,100 as of 2021. This amount in the United States is about 15,000 USD.